Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

8月8日，两家AI制药龙头公司Recursion和Exscientia宣布已达成最终协议合并。Recursion是英伟达力挺的AI制药公司，致力于构建大型生物分子生成式AI模型，以实现药物发现的工业化；Exscientia则是更“传统意义”上的AI制药公司，利用高精度数据进行药物筛选、设计与开发。

In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

此外，她还强调了这家由AI赋能的生物科技公司旗下第二先进的候选药物——REC - 617，称这款口服CDK7抑制剂在铂耐药卵巢癌的治疗中已显现出抗肿瘤潜力，目前针对该适应症的临床开发工作正在有序推进。

根据提交给美国证券交易委员会的Form 4文件显示， RECURSION PHARMACEUTICALS, INC.（纳斯达克股票代码：RXRX） 首席财务官Ben R. Taylor于2025年12月29日以每股4.18美元的价格出售了21,383股A类普通股。此次交易总价值为89,380美元。

智通财经APP获悉，摩根大通将Recursion Pharmaceuticals(RXRX.US)的评级由“中性”上调至“增持”，理由是该公司核心资产REC - 4881具备成为“重磅炸弹”级产品的销售潜力。此外，该行还把Recursion的目标价从10美元提升至11美元。 小摩分析师普里扬卡·格罗弗指出，REC ...

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...